Loading
EREG (Proepiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Non-small-cell lung cancer.
Ligand of the EGF receptor/EGFR and ERBB4. Stimulates EGFR and ERBB4 tyrosine phosphorylation. Contributes to inflammation, wound healing, tissue repair, and oocyte maturation by regulating angiogenesis and vascular remodeling and by stimulating cell proliferation.
CIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Cetuximab and Panitumumab. Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.98, affected pathway 0.88, genetic association 0.00).
In plain words · EREG (Proepiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Non-small-cell lung cancer.
EREG (Proepiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Non-small-cell lung cancer.
Ligand of the EGF receptor/EGFR and ERBB4. Stimulates EGFR and ERBB4 tyrosine phosphorylation.
No product in this corpus aims at EREG yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA EREG: RNA tissue enriched (bone marrow 122 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Colorectal cancer, Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas EREG tissue; Open Targets ENSG00000124882 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Toyoda et al, Biochem. J, 1997, "Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family". Source.
Sources: HGNC HGNC:3443 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O14944 (protein name, function text, keywords and locations (REST API)); CIViC gene EREG (3 evidence items, 0 assertions, 2 variants; diseases: Colorectal Cancer, Lung Adenocarcinoma (GraphQL API, CC0)); Open Targets ENSG00000124882 (association with cancer (MONDO_0004992) 0.64; (GraphQL API, CC0))
Ligand of the EGF receptor/EGFR and ERBB4. Stimulates EGFR and ERBB4 tyrosine phosphorylation. Contributes to inflammation, wound healing, tissue repair, and oocyte maturation by regulating angiogenesis and vascular remodeling and by stimulating cell proliferation. Location: Secreted, extracellular space; Cell membrane (UniProt). Locus 4q13.3 (HGNC).
RNA: tissue enriched (bone marrow 122 nTPM), detected in many normal tissues.
No normal tissue stained high.
RNA cancer enhanced: Colon Adenocarcinoma 18 pTPM, Rectum Adenocarcinoma 23 pTPM.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"EREG" OR ABSTRACT:"EREG" OR TITLE:"epiregulin" OR ABSTRACT:"epiregulin" OR TITLE:"Proepiregulin" OR ABSTRACT:"Proepiregulin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EREG, not a curated reading list.